Pharmacokinetic study of aldoxorubicin in patients with solid tumors
Conclusions Our findings support dosing and administration schemas used in an ongoing phase 3 clinical study of aldoxorubicin in soft tissue sarcoma, and phase 2 clinical studies in small cell lung cancer, glioblastoma, and Kaposi’s sarcoma.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Drugs & Pharmacology | Heart | Investigational New Drugs | Lung Cancer | Sarcomas | Study